Tracking PPM1D post-treatment prevalence to evaluate prognosis in lung adenocarcinoma
Liquid biopsy tracking reveals PPM1D mutations as an emerging biomarker for poor survival
A) 
B)
Figure 1: A) PPM1D prevalence in xF samples relative to non-EGFR targeted 1L therapy in Lung Adenocarcinoma. Samples are not patient matched. B) Real-world overall survival from time of xF sample based on presence of PPM1D mutation.
Lens Library
